VFinance Issues Report on Drug-Eluting Stent Technology; Firm Identifies Companies That Have the Most to Gain or Lose

vFinance Issues Report on Drug-Eluting Stent Technology; Firm Identifies Companies That Have the Most to Gain or Lose

Business Editors/Health/Medical Writers

BIOWIRE2K

NEW YORK–(BUSINESS WIRE)–March 25, 2004

vFinance Investments, Inc. (OTCBB:VFIN), a leading financial services firm providing research, investment banking and brokerage services to corporate, institutional and private clients, has released a sector report analyzing the impact Drug-Eluting Stent (DES) technology will have on the medical device industry. The report identifies those firms that have the most to gain and lose for the adoption of DES.

DES is a revolutionary technology for the treatment of coronary artery disease. vFinance’s proprietary Entrepreneurial Confidence Index (ECI), which measures entrepreneur and private equity investor interest identified medical supplies and devices as an area showing significant increase in activity. Further investigation resulted in the identification of DES as a new technology that was getting a lot of entrepreneur and investor interest.

Drug-Eluting Stents are wire-mesh cylinders coated with pharmaceuticals and inserted into arteries or blood vessels to prevent restenosis, the re-narrowing or clotting of a diseased artery, after angioplasty surgery. This revolutionary technology is changing interventional cardiology by allowing cardiologists to treat more patients utilizing angioplasty rather than open heart surgery, thereby cutting medical costs and improving patient recovery prospects.

Citing industry data, vFinance research analyst Carmelo Troccoli notes: “The DES market is expected to grow 25% year-over-year to $6.3 billion by 2008. The new devices have been proven to reduce restenosis by 60.0% to 70.0% when compared to bare-metal stents, and surgery cost by 50% when compared to invasive coronary artery bypass graft surgery.”

“vFinance’s Entrepreneurial Confidence Index, gives us the ability to identify innovation at its earliest stages,” said Ken McCarthy, chief economist at vFinance Investments, Inc. “Our ability to alert clients to the earliest indications of emerging technologies and industries gives them invaluable investor insight.”

The report features six public companies that participate in the DES space: Medtronic, Inc. (NYSE:MDT), Boston Scientific Corporation (NYSE:BSX), Angiotech Pharmaceuticals, Inc. (Nasdaq:ANPI), SurModics, Inc. (Nasdaq:SRDX), Endovasc, Inc. (OTCBB:EVSC) and MIV Therapeutics, Inc. (OTCBB:MIVT).

About vFinance:

vFinance, Inc. is a rapidly growing financial services company that provides research, investment banking, brokerage and trading services to more than 10,000 corporate, institutional and private clients worldwide. The Company has offices in New York, San Jose, Houston, Boca Raton and 24 other cities nationwide. Its subsidiary, vFinance Investments, Inc., is a registered broker-dealer with the SEC and a member of the NASD.

http://www.vfinance.com, the company’s Web site, is a leading destination on the Internet for companies seeking capital, as well as institutional and high net-worth investors seeking dynamic high-growth companies. Each year, the site hosts more than one million visitors from over 90 countries. This audience creates a perpetual, global deal stream for vFinance’s bricks-and-mortar financial service units and enables vFinance Investments’ Research Department to identify emerging trends, market segments and pioneering firms.

For vFinance Investors

This release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release, which are not strictly historical statements, including, without limitation, statements by management, statements concerning internal operations, marketing, management’s plans, objectives and strategies, and management’s assessment of market factors and conditions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements, including, without limitations, the volatility of domestic and international financial, bond and stock markets, intense competition, extensive governmental regulation, litigation, substantial fluctuations in the volume and price level of securities and other risks as detailed in the Company’s filings with the Securities and Exchange Commission. vFinance assumes no obligation to update any forward-looking information in this press release.

Information regarding securities issues and markets is obtained from sources believed to be reliable, but is not guaranteed as to accuracy, completeness, or fitness to a particular use. This is not an order entry system; please do not convey securities orders via e-mail, as vFinance cannot be responsible for their timely handling. vFinance and its affiliates reserve the right to monitor all e-mail communications, and cannot guarantee the confidentiality of any transmission. The information contained in this transmission is intended solely for the individual or entity to which it is addressed and may contain sensitive material. Any review, storage, re-transmission of, or taking action in reliance upon, this information by persons other than the intended recipient is prohibited. If you have received this email in error please notify the sender and delete the original. This message is not a solicitation of any transaction.

For more information on the Drug-Eluting Stents (DES) sector report, or a copy of the report, please contact:

COPYRIGHT 2004 Business Wire

COPYRIGHT 2004 Gale Group